We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
IDEXX Laboratories Inc | NASDAQ:IDXX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
10.06 | 2.06% | 499.30 | 494.43 | 500.40 | 500.48 | 484.03 | 484.03 | 529,834 | 00:33:56 |
Delaware
|
000-19271
|
01-0393723
|
(State or other jurisdiction
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
of incorporation)
|
|
|
One IDEXX Drive, Westbrook, Maine
|
04092
|
(Address of principal executive offices)
|
(ZIP Code)
|
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
(a)
|
Maturity Date:
The entire outstanding principal balance of the Series C Notes is due and payable on March 14, 2029 (the "
Maturity Date
").
|
(b)
|
Interest:
The Series C Notes bear interest at the rate of 4.19% per annum. Interest payments are due semi-annually in arrears on March 14 and September 14 of each year, commencing on September 14, 2019. All accrued but unpaid interest due is payable on the Maturity Date.
|
(c)
|
Prepayment, Acceleration and Events of Default:
The obligations of the Company under the Series C Notes may be accelerated upon the occurrence of an event of default under the Agreement, which includes customary events of default including, without limitation, payment defaults, defaults in the performance of affirmative and negative covenants, the inaccuracy of representations or warranties, bankruptcy and insolvency related defaults, defaults relating to judgments, an ERISA event and the failure to pay specified indebtedness.
|
(d)
|
Covenants:
The Agreement contains affirmative, negative and financial covenants customary for agreements of this type. The negative covenants include restrictions on liens, indebtedness of subsidiaries of the Company, priority indebtedness, fundamental changes, investments, transactions with affiliates, certain restrictive agreements and violations of laws and regulations. The financial covenant is a consolidated leverage ratio test. The obligations of the Company will be unconditionally guaranteed by each of its subsidiaries that guarantees the obligations of the Company under a material credit facility (but excluding any foreign subsidiary that does not guarantee indebtedness of the Company or any US subsidiaries under a material credit facility).
|
|
(d)
Exhibits.
|
|
IDEXX LABORATORIES, INC.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date: March 15, 2019
|
By:
|
/s/ Brian P. McKeon
|
|
|
|
Brian P. McKeon
|
|
|
|
Executive Vice President, Chief Financial
Officer and Treasurer
(Principal Financial and Accounting Officer)
|
|
1 Year IDEXX Laboratories Chart |
1 Month IDEXX Laboratories Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions